You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
京新藥業(002020.SZ):鹽酸普拉克索片、鹽酸普拉克索緩釋片擬中選第四批全國藥品集採
格隆匯 02-03 18:58

格隆匯 2 月 3日丨京新藥業(002020.SZ)公佈,202123日,公司參加了國家組織藥品集中採購和使用聯合採購辦公室(聯合採購辦公室)組織實施的批國家組織藥品集中採購招投標公司已通過仿製藥質量和療效一致性評價的藥品鹽酸普拉克索片鹽酸普拉克索緩釋片在此次招投標中擬中擬中產品基本情況:

鹽酸普拉克索片擬中選企業為3,鹽酸普拉克索緩釋片擬中選企業為4根據聯合採購辦公室發佈的《全國藥品集中採購文件(GY-YD2021-1)》文件全國實際中選企業數為3家的,為首年約定採購量計算基數的70%;全國實際中選企業數4家及以上的,為首年約定採購量計算基數的80%。全國實際中選企業數為3家的,本輪採購週期原則上為2全國實際中選企業數為4家及以上的,本輪採購週期原則上為3年。採購週期內採購協議每年一簽。續簽採購協議時,約定採購量原則上不少於各地該中選藥品上年約定採購量。採購週期內若提前完成當年約定採購量,超出部分中選企業仍按中選價進行供應,直至採購週期屆滿。

此次公司鹽酸普拉克索片鹽酸普拉克索緩釋片中選有利於進一步擴大其市場覆蓋和銷售,提升公司品牌影響力,並對公司業績產生積極的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account